We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug News
    • Trending
    • Commercial Operations
    • GMPs
    • FDA Enforcement Actions
    • Inspections and Audits
    • Postmarket Safety
    • Quality
    • Regulatory Affairs
    • Research and Development
    • Submissions and Approvals
    • FDAnews Drug Weekly
    • FDAnews
  • Device News
    • Trending
    • Commercial Operations
    • FDA Enforcement Actions
    • Inspections and Audits
    • Postmarket Safety
    • Quality
    • Regulatory Affairs
    • Research and Development
    • Submissions and Approvals
    • FDAnews Device Weekly
    • FDAnews
  • Books
    • FDAnews Books Library
    • Drug Books
    • Device Books
  • Training/Events
    • Webinar Training Pass
    • Events
  • Resources
    • Form 483s Database
    • FDA Approved Drugs
    • White Papers
  • CenterWatch
  • About Us
    • The Company
    • FDAnews Editorial Board
    • Contact Us
  • Advertising
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » REPORT: U.S. FEDERAL HEALTHCARE COSTS TO MORE THAN DOUBLE OVER NEXT 10 YEARS

REPORT: U.S. FEDERAL HEALTHCARE COSTS TO MORE THAN DOUBLE OVER NEXT 10 YEARS

January 25, 2007

In a development likely to fuel the argument that Medicare and Medicaid need major overhauls, the Congressional Budget Office (CBO) is predicting that these programs will grow by 124 percent over the next 10 years, outpacing economic growth two to one.

In its Jan. 24 report, "The Budget and Economic Outlook: Fiscal Years 2008 to 2017," the CBO concluded that while healthcare spending will jump by 124 percent, the gross domestic product is only expected to grow by 63 percent during that time. "Aging of the population and continuing increases in healthcare costs are expected to put considerable pressure on the budget in coming decades," the CBO said.

Economic growth alone is not enough to overcome the rise in healthcare spending, the CBO said. Instead, a drop in healthcare spending, an increase in taxes or some combination of the two is "necessary to promote the nation's long-term fiscal stability."

While the CBO did conclude that Medicare has played a role in recent deficit reductions, it is only a short-term improvement, the agency said. Medicare outlays for that program over the 2007-2016 period are nearly 8 percent lower in this baseline than in the CBO's August 2006 projections, the report said. That reduction is largely attributable to new estimates of per capita costs for all Medicare benefits and lower projections of the number of enrollees in the prescription drug benefit program.

"Those recent changes, however, do not significantly alter the upward trajectory of Medicare spending in the long term," the CBO said.

The report is available at mirror2.cbo.gov/ftpdocs/77xx/doc7731/01-24-BudgetOutlook.pdf.

KEYWORDS Daily International Pharma Alert

    Upcoming Events

    • 28Sep

      The Cost of Counterfeiting: Why You Need a Plan to Secure Your Medical Device Supply Chain

    • 28Sep

      Calculating Sample Size to Satisfy FDA Expectations

    • 11Oct

      GMP Quality Management vSummit 2023: Where Quality Meets Risk

    • 16Oct

      MAGI@home Clinical Research Conference 2023

    • 26Oct

      FDA in 2024: What to Expect in an Election Year

    • 08Nov

      18th Annual FDA Inspections vSummit

    Featured Products

    • FDA, FTC and DOJ Enforcement of Medical Device Regulations

      FDA, FTC and DOJ Enforcement of Medical Device Regulations

    • Using Real-World Evidence in Drug and Device Submissions

      Using Real-World Evidence in Drug and Device Submissions

    Featured Stories

    • Manufacturing Cost is Key Issue Facing Gene Therapy Products, Marks Says

    • Artificial Womb Technology Not Yet Ready for Human Trials Adcomm Says

    • Top Concern for CBER is Marketing of Unapproved Biologics, Says FDA Official

    • FDA Deems Medline Industries’ Saline Solution Vial Recall as Class 1

    The Revised ICH E8: A Guide to New Clinical Trial Requirements

    Learn More
    • Drug Products
      • Quality
      • Regulatory Affairs
      • GMPs
      • Inspections and Audits
      • Postmarket Safety
      • Submissions and Approvals
      • Research and Development
      • Commercial Operations
    • Device Products
      • Quality
      • Regulatory Affairs
      • QSR
      • Inspections and Audits
      • Postmarket Safety
      • Submissions and Approvals
      • Research and Development
      • Commercial Operations
    • Clinical Products
      • Trial Design
      • Data Integrity
      • GCP
      • Inspections and Audits
      • Transparency
    • Privacy Policy
    • Do Not Sell or Share My Data
    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing